The Journal of Urology
Volume 183, Issue 1 , Pages 27-33 , January 2010

Contemporary Applications and Limitations of Magnetic Resonance Imaging Contrast Materials

  • Ricardo A. Natalin

      Affiliations

    • Department of Urology, Columbia University School of Medicine, New York, New York
    • ,
  • Martin R. Prince

      Affiliations

    • Department of Radiology, Columbia University School of Medicine, New York, New York
    • Department of Radiology, Weill Cornell Medical College, New York, New York
    • ,
  • Marc E. Grossman

      Affiliations

    • Department of Dermatology, Columbia University, New York Presbyterian Medical Center, New York, New York
    • ,
  • David Silvers

      Affiliations

    • Department of Dermatology, Columbia University, New York Presbyterian Medical Center, New York, New York
    • ,
  • Jaime Landman

      Affiliations

    • Department of Urology, Columbia University School of Medicine, New York, New York
    • Corresponding Author InformationCorrespondence: 161 Fort Washington Ave., 11th Floor, New York, New York 10023 (telephone: 212-305-5630; FAX: 212-342-0694)

Received 5 April 2009

References 

  1. Dussol B, Morange S, Loundoun A, et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant. 2006;21:2120
  2. Reed PS, Dixon SR, Boura JA, et al. Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. Am J Cardiol. 2007;100:1090
  3. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000
  4. Grobner T. Gadolinium (A specific trigger for the development of nephrogenic systemic fibrosing dermopathy and nephrogenic systemic fibrosis?). Nephrol Dial Transplant. 2006;21:1104
  5. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?. Semin Dial. 2008;21:129
  6. Bussi S, Fouillet X, Morisetti A. Toxicological assessment of gadolinium release from contrast media. Exp Toxicol Pathol. 2007;58:323
  7. Lucas RL, Benjamin M, Reineke TM. Comparison of a tartaric acid derived polymeric MRI contrast agent to a small molecule model chelate. Bioconjug Chem. 2008;19:24
  8. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd-Hp-DO3A (ProHance) retention in human bone tissue by inductive coupled plasma atomic emission spectroscopy. Invest Radiol. 2004;39:138
  9. Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563
  10. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol. 2008;3:747
  11. Brown JJ, Hynes MR, Wible JH. Measurement of serum calcium concentration after administration of four gadolinium-based contrast agents to human volunteers. AJR Am J Roentgenol. 2007;189:1539
  12. Rodby RA. Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients. Semin Dial. 2008;21:145
  13. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23:383
  14. Ting WW, Stone MS, Madison KC, et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903
  15. Cowper SE. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. http://www.icnfdr.org2001–2007;Accessed April 8, 2008.
  16. Cowper SE: Nephrogenic systemic fibrosis: an update. Presented at 2nd Annual Scientific Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-Containing Contrast Agents, New Haven, Connecticut, May 10, 2008.
  17. Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis-Implications for nephrologists. Eur J Radiol. 2008;66:208
  18. Kalb RE, Helm TN, Sperry H, et al. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol. 2008;158:607
  19. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link?. Clin J Am Soc Nephrol. 2007;2:200
  20. Shenoy C. Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney and liver disease. Am J Med. 2008;121:e11
  21. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med. 2006;145:234
  22. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148
  23. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807
  24. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264
  25. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am Roentgenol. 2007;188:586
  26. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141
  27. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent ‘activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol. 2008;214:584
  28. Bucala R, Spegel LA, Chesney J, et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994;1:71
  29. Bucala R. Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol. 2008;5:36
  30. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65
  31. Bosch E, Kreitner KF, Peirano MF, et al. Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase 3 study. AJR Am J Roentgenol. 2008;190:179
  32. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol. 2007;18:2636
  33. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:191
  34. Chesney J, Bucala R. Peripheral blood fibrocytes: mesenchymal precursor cells and the pathogenesis of fibrosis. Curr Rheumatol Rep. 2000;2:501
  35. Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol. 2008;3:968
  36. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359
  37. Gilliet M, Cozzio A, Burg G, et al. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152:531–536
  38. Othersen JB, Maize JC, Woolson RF, et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant. 2007;22:3179
  39. Pieringer H, Schmekal B, Janko O, et al. Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3094
  40. Introcaso CE, Hivnor C, Cowper S, et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol. 2007;46:447
  41. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58:2543
  42. Saitoh T, Hayasaka K, Tanaka Y, et al. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med. 2006;24:445
  43. Food and Drug Administration Public Alert 06/2006, updated 12/2006 and 5/23/2007: GBC agents for magnetic resonance imaging Marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). http://www.fda.gov/cder/drug/InfoSheets/ 2007_05HCP.pdfAccessed April 8, 2008.
  44. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188:1447
  45. Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency?. MAGMA. 2007;20:57
  46. Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents. Dear Healthcare Professional Communication (MHRA Communication dated February 7, 2007). http://www.mhra.gov.uk/SearchHelp/Search/Searchresults/index.htm?within=Yes&keywords=gadoliniumAccessed April 8, 2008.

 Nothing to disclose.

 Editor's Note: This article is the second of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 404 and 405.

PII: S0022-5347(09)02460-4

doi: 10.1016/j.juro.2009.09.029

The Journal of Urology
Volume 183, Issue 1 , Pages 27-33 , January 2010

Article Tools